Valsartan is an antihypertensive drug

Valsartan is a specific angiotensin II (AT1) receptor antagonist, and is another non-skinned AT1 receptor antagonist used in clinical applications after losartan. It regulates systemic blood pressure and maintains electrolyte fluid. The balance plays a key role. It selectively acts on the AT1 receptor subtype, blocking the binding of AngII to the AT1 receptor (which specifically antagonizes the AT1 receptor by about 20,000 times greater than the AT2 receptor), thereby inhibiting vasoconstriction and aldosterone release. Antihypertensive effect, but does not inhibit aldosterone release caused by potassium ion (K+). The antihypertensive effect is better than enalapril, which is suitable for the treatment of antihypertensive, mild to moderate essential hypertension, especially for secondary hypertension caused by kidney damage, which can significantly reduce the high incidence of diabetes or normal renal function. The proteinuria of blood pressure patients has a kidney protection effect that promotes uric acid and urinary sodium excretion. It is also suitable for reducing cardiovascular mortality in high-risk patients (left ventricular failure or left ventricular dysfunction) after a heart attack.
A clinical trial has shown that valsartan is very effective in treating mild to moderate hypertension. A single dose of ≥80mg can effectively control systolic and diastolic blood pressure for 24h without changing the rhythm of blood pressure change; 160mg once a day is more effective than losartan 100mg once a day. Patients with moderate hypertension and intact renal function have good tolerance to valsartan, and the curative effect is significantly better than that of invertase inhibitors, and the adverse reactions are mild. Combined with other antihypertensive drugs is effective for severe hypertension.